World Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes October 20, 2025 12:03 pm Kevin Kunzmann 0 Min Read SHARE Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic. This post was originally published on this site Previous Article From Capstone to Career: UNO MBA Alumni Find Real-World Success Next Article Iphone 17 Pro Max: Says goodbye to battery woes